Compare FFIV & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FFIV | VTRS |
|---|---|---|
| Founded | 1996 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Computer Communications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 17.2B |
| IPO Year | 1999 | 2019 |
| Metric | FFIV | VTRS |
|---|---|---|
| Price | $322.72 | $14.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $312.88 | $13.50 |
| AVG Volume (30 Days) | 730.0K | ★ 8.3M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ 23.56 | N/A |
| EPS | ★ 3.10 | N/A |
| Revenue | $3,088,072,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $8.00 | $4.41 |
| Revenue Next Year | $3.27 | $1.96 |
| P/E Ratio | $104.37 | ★ N/A |
| Revenue Growth | ★ 9.66 | N/A |
| 52 Week Low | $223.76 | $8.19 |
| 52 Week High | $346.00 | $16.47 |
| Indicator | FFIV | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 62.17 | 64.68 |
| Support Level | $317.66 | $12.90 |
| Resistance Level | $335.42 | $15.22 |
| Average True Range (ATR) | 9.49 | 0.39 |
| MACD | 1.40 | 0.09 |
| Stochastic Oscillator | 78.75 | 88.03 |
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.